Tryton Medical, Inc. Announces Investigational Device Exemption Conditional Approval from FDA to Conduct U.S. Pivotal Study of Side Branch Stent
DURHAM, N.C.--(BUSINESS WIRE)--Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced U.S. Food and Drug Administration (FDA) conditional approval for an Investigational Device Exemption (IDE) application to initiate the pivotal trial to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery disease.